Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

ABLBio (298380 KS): Continued License Out Deals and Milestone Payment Realization to Feed Pipeline

ABLBio (298380 KS): Funding From Lilly To Strengthen Drug Development Capabilities

ABL Bio: Equity Investment of 22 Billion Won from Eli Lilly

Eli Lilly’s Q3 Earnings: Mounjaro Is Taking the World by Storm—See How It’s Conquering New Markets!

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/ablbio-inc" target="_blank" data-smartkarma-citation="entities:35621:1" rel="noopener">ABLBio (298380 KS)</a>'s ADC drug candidate ABL111 (givastomig) enters global Phase 2 clinical trial for metastatic gastric cancer. Top line Phase 2 results are expected in 2027.  </li>
<li>Positive Phase 1b data position givastomig to be a potential best-in-class CLDN18.2-directed therapy for gastric cancer, which has a projected $12B market opportunity by 2030.</li>
<li>Last month, FDA approved clinical trial application for a Phase 1 trial of ABL206. ABL206 is the first candidate from ABL Bio’s next-generation ADC pipeline to enter the clinical stage.</li>
</ul>



ABLBio (298380 KS)'s ADC drug candidate ABL111 (givastomig) enters global Phase 2 clinical trial for metastatic gastric cancer. Top line Phase 2 results are expected in 2027.  
Positive Phase 1b data position givastomig to be a potential best-in-class CLDN18.2-directed therapy for gastric cancer, which has a projected $12B market opportunity by 2030.
Last month, FDA approved clinical trial application for a Phase 1 trial of ABL206. ABL206 is the first candidate from ABL Bio’s next-generation ADC pipeline to enter the clinical stage.


ABLBio (298380 KS): Pipeline Is Progressing Toward Commercialization